Hypoactive Sexual Desire Disorder

Many midlife women experience hypoactive sexual desire disorder, which can impact both relationships and mental health, but two FDA approved treatments are available, according to a speaker at the Annual Meeting of The Menopause Society.

CHICAGO — Many midlife women experience hypoactive sexual desire disorder, impacting both partner relationships and mental health, but FDA-approved treatments are available, according to a speaker.

Kisspeptin was associated with enhanced sexual brain processing, increased penile tumescence and multiple measures of sexual desires and arousal among men with hypoactive sexual desire disorder, according to a study data.

Intravenous kisspeptin was associated with brain processing of erotic stimuli and facial attractiveness and was well tolerated by premenopausal women with hypoactive sexual desire disorder, according to study data.